PHusis Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- PHusis Therapeutics's estimated annual revenue is currently $930k per year.
- PHusis Therapeutics's estimated revenue per employee is $155,000
Employee Data
- PHusis Therapeutics has 6 Employees.
- PHusis Therapeutics grew their employee count by -14% last year.
PHusis Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Scientist II | Reveal Email/Phone |
PHusis Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is PHusis Therapeutics?
PHusis is designing precision medicines using its proprietary computational modeling platform, PHuDock to rapidly identify inhibitors of proteins with regulatory PH-domains that drive cancer growth. The approach provides PHusis with the means of identifying drug leads more rapidly and in a cost-effective manner. The result is, PHusis has built a pipeline of drug leads against some novel and critical cancer targets including PDK1, mutant KRAS and NRAS. Patients can be selected for treatment based on their mutational profile, eliminating unnecessary treatment of patients without the targets
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 6 | -25% | N/A |
#2 | $0.4M | 6 | N/A | N/A |
#3 | $0.4M | 6 | N/A | N/A |
#4 | $0.4M | 6 | N/A | N/A |
#5 | $0.4M | 6 | N/A | N/A |